{
  "resourceType": "Evidence",
  "id": "evidence-cervical-cancer-rational",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong>Importance</strong></p>\r\n<p>The number of deaths from cervical cancer in the United States have decreased substantially since the implementation of widespread cervical cancer screening and continue to decline, from 2.8 per 100,000 women in 2000 to 2.3 deaths per 100,000 women in 2015.1 Most cases of cervical cancer occur among women who have not been adequately screened.2 Strategies that aim to ensure that all women are appropriately screened and receive adequate follow-up are most likely to succeed in further reducing cervical cancer incidence and mortality in the United States.</p>\r\n<p>&nbsp;</p>\r\n<p><strong>Detection</strong></p>\r\n<p>The USPSTF found convincing evidence that screening with cervical cytology alone, primary testing for high-risk HPV types (hrHPV testing) alone, or in combination at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer.</p>\r\n<p>&nbsp;</p>\r\n<p><strong>USPSTF Assessment</strong></p>\r\n<p>The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone, every 5 years with hrHPV testing alone, or in combination in women aged 30 to 65 years outweigh the harms.</p>\r\n<p>&nbsp;</p>\r\n<p>The USPSTF concludes with moderate certainty that the benefits of screening in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer do not outweigh the potential harms.</p>\r\n<p>&nbsp;</p>\r\n<p>The USPSTF concludes with moderate certainty that the harms of screening in women younger than 21 years outweigh the benefits.</p>\r\n<p>&nbsp;</p>\r\n<p>The USPSTF concludes with high certainty that the harms of screening in women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer outweigh the benefits.</p></div>"
  },
  "title": "Screening for Cervical Cancer Rational",
  "status": "active",
  "assertion": "<p><strong>Importance</strong></p><p>The number of deaths from cervical cancer in the United States have decreased substantially since the implementation of widespread cervical cancer screening and continue to decline, from 2.8 per 100,000 women in 2000 to 2.3 deaths per 100,000 women in 2015.1 Most cases of cervical cancer occur among women who have not been adequately screened.2 Strategies that aim to ensure that all women are appropriately screened and receive adequate follow-up are most likely to succeed in further reducing cervical cancer incidence and mortality in the United States.</p><p>&nbsp;</p><p><strong>Detection</strong></p><p>The USPSTF found convincing evidence that screening with cervical cytology alone, primary testing for high-risk HPV types (hrHPV testing) alone, or in combination at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer.</p><p>&nbsp;</p><p><strong>USPSTF Assessment</strong></p><p>The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone, every 5 years with hrHPV testing alone, or in combination in women aged 30 to 65 years outweigh the harms.</p><p>&nbsp;</p><p>The USPSTF concludes with moderate certainty that the benefits of screening in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer do not outweigh the potential harms.</p><p>&nbsp;</p><p>The USPSTF concludes with moderate certainty that the harms of screening in women younger than 21 years outweigh the benefits.</p><p>&nbsp;</p><p>The USPSTF concludes with high certainty that the harms of screening in women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer outweigh the benefits.</p>",
  "variableDefinition": [
    {
      "variableRole": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/variable-role",
            "code": "population",
            "display": "population"
          }
        ]
      },

    }
  ]
}